Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.

The discovery of activating BRAF mutations in ∼50% of all melanomas has proved to be a turning point in the therapeutic management of the disseminated disease. In this commentary, we review the latest research delineating the role of mutant BRAF in melanoma initiation and progression and discuss the remarkable 10-year journey leading up to the recent U.S. Food and Drug Administration approval of the small-molecule BRAF inhibitor vemurafenib. We further outline the most recent findings on the mechanisms that underlie intrinsic and acquired BRAF inhibitor resistance and describe ongoing preclinical and clinical studies designed to delay or abrogate the onset of therapeutic escape. It is hoped that our evolving understanding of melanoma genetics and intracellular signaling coupled with a growing armamentarium of signal transduction inhibitors will lead to significant improvements in the level and durability of therapeutic response in metastatic melanoma.

[1]  J. Dering,et al.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. , 2010, Neoplasia.

[2]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[3]  A. Bosserhoff,et al.  Meeting report from the 2011 international melanoma congress, Tampa, Florida , 2012, Pigment cell & melanoma research.

[4]  Hong Wu,et al.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.

[5]  K. Flaherty,et al.  Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. , 2010, Biochemical pharmacology.

[6]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[7]  M. Soengas,et al.  Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. , 2009, Cancer research.

[8]  P. Hersey,et al.  Cancer Therapy : Preclinical MEK-Independent Survival of B-RAFV 600 E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX 4720 , 2011 .

[9]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[10]  M. McMahon,et al.  Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival , 2008, Pigment cell & melanoma research.

[11]  S. Ariyan,et al.  Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 , 2010, Journal of Translational Medicine.

[12]  Chelsea C Pinnix,et al.  Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. , 2006, Cancer research.

[13]  B. Taylor,et al.  Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF , 2012, Oncogene.

[14]  M. Gordon,et al.  RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models , 2010 .

[15]  G. Robertson,et al.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. , 2008, Cancer research.

[16]  T. Golub,et al.  Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. , 2004, Cancer cell.

[17]  K. Flaherty,et al.  Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Flaherty,et al.  Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib , 2009, Clinical Cancer Research.

[19]  P. Guldberg,et al.  Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF , 2005, Oncogene.

[20]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[21]  S. Duensing,et al.  Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers. , 2010, Biochemical pharmacology.

[22]  A. Ribas,et al.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.

[23]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[24]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[25]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[26]  A. Aplin,et al.  B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. , 2007, Molecular biology of the cell.

[27]  Francesca Zappacosta,et al.  GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition , 2011, Clinical Cancer Research.

[28]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[29]  Ultan McDermott,et al.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.

[30]  A. Hauschild,et al.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[32]  R. Marais,et al.  Tumor Necrosis Factor-α Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited , 2007 .

[33]  D. Woods,et al.  Induction of β3-Integrin Gene Expression by Sustained Activation of the Ras-Regulated Raf–MEK–Extracellular Signal-Regulated Kinase Signaling Pathway , 2001, Molecular and Cellular Biology.

[34]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Labow,et al.  Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. , 2011, Cancer research.

[36]  I. S. Dunn,et al.  Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression , 2006, Molecular Cancer Research.

[37]  Michael Krauthammer,et al.  PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells , 2010, Pigment cell & melanoma research.

[38]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[39]  C. Willett,et al.  Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Eisen,et al.  The involvement of p38 mitogen-activated protein kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced melanogenic and anti-proliferative effects in B16 murine melanoma cells. , 2000, FEBS letters.

[41]  C. Rudin,et al.  Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.

[42]  A. Aplin,et al.  Mutant B-RAF mediates resistance to anoikis via Bad and Bim , 2008, Oncogene.

[43]  J. Sosman,et al.  Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[45]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[46]  D. Schadendorf,et al.  RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[48]  K. Smalley,et al.  The involvement of p38 mitogen‐activated protein kinase in the α‐melanocyte stimulating hormone (α‐MSH)‐induced melanogenic and anti‐proliferative effects in B16 murine melanoma cells , 2000 .

[49]  Prahlad T. Ram,et al.  Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. , 2010, Cancer research.

[50]  K. Flaherty,et al.  Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels , 2007, British Journal of Cancer.

[51]  M. Herlyn,et al.  PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas , 2010, Pigment cell & melanoma research.

[52]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[53]  A. Aplin,et al.  Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. , 2009, Cancer research.

[54]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[55]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[56]  N. Dhomen,et al.  BRAF signaling and targeted therapies in melanoma. , 2009, Hematology/oncology clinics of North America.

[57]  E. Sahai,et al.  Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. , 2011, Cancer cell.

[58]  Jonathan Chernoff,et al.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .

[59]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[60]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[61]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[62]  D. Pinkel,et al.  Cyclin D1 is a candidate oncogene in cutaneous melanoma. , 2002, Cancer research.

[63]  Yong-Yeon Cho,et al.  Embryonic stem‐cell‐preconditioned microenvironment induces loss of cancer cell properties in human melanoma cells , 2011, Pigment cell & melanoma research.

[64]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[65]  B. Hemmings,et al.  PKB Binding Proteins Getting in on the Akt , 2002, Cell.

[66]  Steven Whittaker,et al.  Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies , 2010, Science Translational Medicine.

[67]  W. Franklin,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[70]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[71]  V. Sondak,et al.  Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy , 2010, British Journal of Cancer.

[72]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[73]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[75]  M. Herlyn,et al.  The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel , 2008, Clinical Cancer Research.

[76]  D. Elder,et al.  CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations , 2009, Oncogene.

[77]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[78]  G. Schwartz,et al.  A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  D. Pinkel,et al.  MC1R germline variants confer risk for BRAF-mutant melanoma. , 2006, Science.

[80]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[81]  A. Aplin,et al.  Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells , 2011, Oncogene.

[82]  R. Marais,et al.  Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. , 2007, Cancer research.

[83]  V. Sondak,et al.  PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. , 2011, Cancer research.

[84]  P. Hersey,et al.  MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720 , 2010, Clinical Cancer Research.

[85]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[86]  J. Ortonne,et al.  Mitogen-activated Protein Kinase Pathway and AP-1 Are Activated during cAMP-induced Melanogenesis in B-16 Melanoma Cells (*) , 1995, The Journal of Biological Chemistry.

[87]  A. Weeraratna,et al.  Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010 , 2011, Pigment cell & melanoma research.

[88]  K. Flaherty.  Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress , 2011, Pigment cell & melanoma research.

[89]  Paul D. Smith,et al.  The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer , 2010, Clinical Cancer Research.

[90]  P. LoRusso,et al.  Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  P. Hersey,et al.  Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS , 2010, Cell Death and Disease.

[92]  A. Aplin,et al.  Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis , 2009, Molecular Cancer Research.

[93]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[94]  K. Smalley,et al.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. , 2011, Biochemical pharmacology.

[95]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[96]  M. Brown,et al.  Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .

[97]  Keith T Flaherty,et al.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.

[98]  J. Norman,et al.  B-Raf Acts via the ROCKII/LIMK/Cofilin Pathway To Maintain Actin Stress Fibers in Fibroblasts , 2004, Molecular and Cellular Biology.

[99]  R. Dummer,et al.  Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.

[100]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[101]  A. Aplin,et al.  Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. , 2010, Cancer research.

[102]  K. Nathanson,et al.  Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) , 2013, Clinical Cancer Research.

[103]  A. Brunet,et al.  Inhibition of the Mitogen-activated Protein Kinase Pathway Triggers B16 Melanoma Cell Differentiation* , 1998, The Journal of Biological Chemistry.